@article {CauncaS18.004作者={米歇尔Caunca Chuanhui盾和Chensy马尔克斯和肯张Tatjana Rundek和诺姆Alperin唱l·李和艾哈迈德Bagci米切尔艾尔金德和Charles DeCarli唱李和拉尔夫和班斯特恩和克林顿的焦点在于莱特},title ={海马体积和白质高密度与特定领域的认知能力下降:曼哈顿北部研究(S18.004)},体积={88}={16}补充数量,elocation-id = {S18.004} ={2017},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={卷作为目的:检查脑和白质高密度相关领域特定的认知能力下降。首页背景:脑MRI研究纵向神经心理学(NP)的数据在种族/民族多样化的数量是有限的。设计/方法:曼哈顿北部研究(坏疽性口炎)是一个种族/民族多样化,临床stroke-free,前瞻性群组研究\ > 55岁的人。NP测试进行了5年的平均基线。我们(WMHV),量化白质高密度总脑(TCV),侧脑室(电磁阀)总量以及区域灰质体积子样品。我们估计MRI标记之间的联系和变化在特定领域的NP z分数使用多变量线性回归调整了年龄、性别、教育、种族、基线z分数各自的认知领域,生活方式和血管危险因素,APOEɛ4和其他脑容量。我们进行分层分析来评估潜在影响修改年龄,APOEɛ4等位基因或基线认知。结果:NP评估860名参与者,(SD)的平均年龄为69年(8)和62 \ %女,68 \ %拉丁美洲裔,17 \ %的黑色,和13 \ %的白色。的意思是NP z得分(SD)变化对执行功能-0.19(0.84),情景记忆-0.18(0.83),处理速度-0.34(0.66),-0.21(0.66)和语义记忆。大WMHV下降明显与更大的语义(每1 SDβ= -0.08,p = 0.01)和情景记忆(每1 SDβ= -0.09,p = 0.02)的完全调整模型。较大的海马体积能显著减少执行功能下降(每1 sdβ= 0.09,p = 0.02)和情景记忆(每1 sdβ= 0.08,p = 0.03)的完全调整模型。 Participants >=70 years, APOE ɛ4 non-carriers, or those who scored >=24 on a baseline Mini Mental State Examination exhibited less decline with larger hippocampal volumes.Conclusions: White matter disease burden and gray matter volume predicted decline in cognitive performance over time. Greater hippocampal volumes may protect against faster decline.Disclosure: Dr. Caunca has nothing to disclose. Dr. Dong has nothing to disclose. Dr. Marquez has nothing to disclose. Dr. Cheung has received personal compensation for activities with Remedy as a consultant. Dr. Cheung has received research support from IBM. Dr. Rundek has nothing to disclose. Dr. Alperin has received personal compensation for activities with Alperin Noninvasive Diagnostics, Inc. Dr. Lee has nothing to disclose. Dr. Bagci has nothing to disclose. Dr. Elkind has received personal compensation in an editorial capacity for Neurology. Dr. DeCarli has received personal compensation for activities with Novartis Pharmaceuticals as a consultant. Dr. Lee has received research support from Boehringer Ingelheim. Dr. Sacco has received research support from Boehringer Ingelheim Pharmaceuticals. Dr. Stern has received personal compensation for activities with Takeda, Axovant, and Eli Lilly and Company as an advisor and/or consultant. Dr. Stern has received license fees from Columbia. Dr. Stern has received research support from Axovant, Piramal and the California Walnut Commission. Dr. Wright has received royalty payments from UpToDate.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/88/16_Supplement/S18.004}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }